The Science
Extracellular Vesicle
The Body's Cellular Messengers.
At the frontier of regenerative medicine lies a discovery redefining how the body heals — and BICC is building the commercial platform around it.
The Biology
What Are Extracellular Vesicles?
Extracellular Vesicles (EVs) are nanoscale particles secreted by cells. They carry proteins, lipids and RNA — the molecular instructions that tell surrounding cells to repair, regenerate and rebalance. They are the communication system of regeneration.
MSC-derived EVs carry much of the regenerative benefit of stem-cell therapy — without the risks or regulatory complexity of live-cell transplantation. More stable, more scalable, and more commercially viable than any approach that came before.
BICC's platform is built on this science — a rapidly maturing field with applications spanning cosmeceuticals, wound care, metabolic health conditions such as diabetes and fatty liver disease, and neurodegeneration. BICC commercialises it in staged, capital-efficient phases, beginning where the science is most mature and the path to market is clearest.
Application areas: cosmeceuticals · wound care · diabetes support · fatty liver disease · neurodegeneration
Three Problems BICC Solves
Scalable Commercialisation Has Been
Blocked by Three Problems.
BICC's platform directly addresses all three.
PROBLEM 1
Donor Variability
MSC potency differs dramatically between donors. Most companies screen after production — incurring 6–12 months of delay and significant cost.
BICC's Solution
BICC identifies high-potency donors prospectively, eliminating retrospective screening.
~40–60%
lower screening cost
Problem 2
Manufacturing Consistency
Inconsistent cell supply undermines product quality and the batch-to-batch reliability regulators require.
BICC's Solution
Optimised immortalised MSC lines provide a uniform, unlimited cell supply.
Uniform
unlimited cell supply
Problem 3
Production Scalability
Lab-scale processes cannot reach the volumes commercial and clinical use demand.
BICC's Solution
A defined, scalable, cGMP-compliant workflow. Bioreactor scale-up in progress.
3–5L
per batch · 9–14 day cycle
The A*STAR Collaboration
Research Collaboration Agreement with
Singapore's National Research Agency.
BICC has signed a Research Collaboration Agreement (RCA) with A*STAR — providing institutional scientific backing and a structured pathway to commercialisation.
Scope
Joint development of MSC-derived EV applications, drawing on A*STAR's research capability and BICC's commercial platform. A*STAR scientists work alongside BICC.
IP Co-Ownership
IP arising from BICC's own contribution is co-owned — BICC's share increasing in proportion to its scientific and commercial input.
BICC's Rights
Priority rights to cosmeceutical applications from the EV output — speed to market, backed by institutional science.
Timeline
First commercial cosmeceutical application targeted within 18 months of RCA signing — with a structured development and commercialisation pathway already underway.
Commercial Roadmap
Starts with Skincare.
Leads to Therapeutics.
A staged path balancing speed to revenue with scientific integrity — each phase funds and validates the next.
Phase 1 · Near-Term · 2026
Cosmeceuticals & Wound Care
The beachhead — lower regulatory barrier, fast to market.
-
EV-infused serums, face masks and eye patches
-
EV-based wound care and tissue repair products
-
Cosmeceutical rights from the A*STAR RCA
-
H2 2026 first shipments — Singapore, China & Thailand
-
Three distribution channels established — 300+ clinic touchpoints
Phase 2 · Medium-Term · 2027–28
Expanded Clinical Applications
Broader reach, deeper clinical validation, higher-margin products.
-
EV wound care advancing through international certification — further regulatory approvals in progress to support global distribution
-
Two clinic pilots in active discussion
-
EV-based support products targeting diabetes and fatty liver disease
Phase 3 · Long-Term · 2029+
Therapeutics & Licensing
Where the platform compounds into its full long-term value.
-
Therapeutic pipeline: diabetes, fatty liver disease, neurodegeneration
-
Out-licensing to major pharma and healthcare partners
-
Pharma R&D partnerships & contract manufacturing
Medical & Scientific Advisory
The Minds Behind the Science.
BICC's research and clinical direction is guided by an advisory team that brings together deep pharmacological expertise, biomedical science leadership, and frontline clinical practice — ensuring the science is both rigorous and practically grounded.
Chief Science Advisor
Dr Kampon Sriwatanakul
M.D., Ph.D.
"The Godfather of Stem Cell Therapy in Thailand and one of the world's foremost pioneers in regenerative medicine."
Chairman of the Thailand Charter of Health and a world-recognised authority in stem cell science, cell therapy and anti-ageing medicine.
Over four decades at the frontier of regenerative medicine — developing protocols adopted across Asia, training a generation of clinicians, and shaping the global conversation on EV science and functional medicine. Dr Kampon's counsel defines the scientific ambition of the BICC platform.
AREAS OF EXPERTISE
• Stem Cell Therapy
• Cell Therapy Pioneer
• Regenerative Medicine
• Functional Medicine
• Anti-Ageing
Lead Scientist
Dr Ron Tan Eng Lee
Ph.D. in Biomedical Science, NUS · Senior Research Fellow, NUS
20+ years translating biomedical science into clinical and commercial reality across SEA. Former Head of Business & Industry Development at A*STAR Infectious Diseases Labs (SGD $30M+ in research funding secured).
Built and led clinical genomics labs across six countries. Senior Research Fellow at NUS · Industry Advisor at Singapore Institute of Technology. 35+ international publications · 5 patents.
AREAS OF EXPERTISE
• Biomedical Science
• Genomics & Diagnostics
• Lab-to-Market
• Precision Medicine
Clinical Advisor · GP, Aesthetics & Microbiome
Dr Lim Kim Show
MBBS (NUS, 1995) · Grad. Diploma in Family Medicine (UK) · Certified Laser Physician
Singapore GP and aesthetic medicine specialist with a deep clinical focus on gut health and the microbiome — the perfect bridge between BICC's Longevity Stack™ and frontline patient care.
One of Singapore's pioneers in clinical laser therapy (certified since 2000), with 30+ years integrating aesthetic medicine, acupuncture and preventive health.
MBBS NUS · Grad. Diploma in Family Medicine (UK) · MOH-appointed primary care architect.
AREAS OF EXPERTISE
• Gut & Microbiome
• Aesthetic Medicine
• Family Medicine
• Preventive Health
Why BICC
Science That Pays for Itself.
Built to Scale.
Most regenerative medicine companies are entirely dependent on external funding to sustain their research. BICC is structured differently — our health services and infrastructure businesses generate operating revenue today, funding the EV science platform without diluting the mission or the timeline.
The result is a platform that can move at the pace of science, not the pace of fundraising — advancing Extracellular Vesicle technology from cosmeceuticals to clinical applications, anchored by a signed Research Collaboration Agreement with A*STAR, Singapore's national research agency.
Intellectual Property
The Patent Portfolio.
The Moat.
BICC's five-patent portfolio spans the full value chain of EV therapy — from upstream cell culture to downstream formulation and delivery. This integrated IP position is the scientific moat that protects BICC's commercial advantage.
P01
Stem Cell Culture & Expansion System
GRANTED
Regenerative Medicine :
A proprietary method for culturing and expanding mesenchymal stem cells at clinical scale, maintaining phenotypic stability across multiple passages — the foundational platform for all downstream EV production.
P02
Exosome Biologic Isolation & Purification
GRANTED
EV Therapy :
A novel multi-step isolation protocol that achieves >95% purity of therapeutic EVs from conditioned media, eliminating cellular debris and non-vesicular contaminants that compromise therapeutic efficacy.
P03
Regenerative Wound Healing Formulation
GRANTED
Wound Care :
An EV-enriched topical formulation that accelerates wound closure by 40% vs. standard of care in preclinical models, with applications in diabetic wound management, burns, and post-surgical recovery.
P04
Cryopreservation Protocol for EV Biologics
FILED
Manufacturing :
A stabilisation and cryopreservation methodology that preserves >90% of EV biological activity after freeze-thaw cycles, enabling global distribution of EV therapeutics without cold-chain compromise.
P05
Immune Cell Activation & Modulation Platform
FILED
Immunotherapy :
A platform for EV-mediated immune cell modulation, enabling targeted activation or suppression of immune responses — with applications in autoimmune disease, cancer immunotherapy, and aging-related immune decline.
Clinical Pipeline
From Lab to Market.
A Defined Pathway.
INDICATION | STAGE | TIMELINE | PARTNER |
|---|---|---|---|
Neurodegenerative Disease | Discovery | Preclinical: 2028 | BICC Internal |
Age-Related Immune Decline | Research | IND Filing: 2027 | BICC Internal |
Metabolic Syndrome | Research | IND Filing: 2027 | Biotech & Biomedicine (Shenyang) |
Regenerative Wound Healing | Preclinical | Phase I: 2026 | Beijing Tianyi Yuanfang |
Longevity Nutraceuticals (TSG) | Commercial | Live — 2024 | The Stemcell Group |